{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"ARION","nct_id":"NCT03777813","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=arion-nct03777813. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ARION","arms":[{"description":"Concomitant administration of durvalumab (dose: 1500 mg):\n\nEvery 4 weeks during concurrent FOLFOX and after FOLFOX completion (total of 12 months of treatment)\n\nDefinitive modulated-intensity radiotherapy will be delivered according to boost integrated technique 5 days a week for 5 weeks at a dose of:\n\n* 50 Gy delivered in 25 fractions to the macroscopic disease (endoscopic, TDM and fused FDG PET)\n* 45 Gy to the adjacent peri tumoral mucosis and prophylactic lymph node\n\nFOLFOX 4 simplified protocol, 1 infusion every 2 weeks during 3 months starting with radiotherapy (+/- 1 day):\n\n* IV oxaliplatin 85 mg/m² in 2 h on D1\n* IV Leucovorin 200 mg/m² in 2 h on D1, followed by\n* IV 5-FU 400 mg/m² in 10 minutes on D1 followed by\n* IV continuous infusion 5-FU 2400 mg/m² in 46 h","label":"Arm A","type":"EXPERIMENTAL"},{"description":"Definitive modulated-intensity radiotherapy will be delivered according to boost integrated technique 5 days a week for 5 weeks at a dose of:\n\n* 50 Gy delivered in 25 fractions to the macroscopic disease (endoscopic, TDM and fused FDG PET)\n* 45 Gy to the adjacent peri tumoral mucosis and prophylactic lymph node\n\nFOLFOX 4 simplified protocol, 1 infusion every 2 weeks during 3 months starting with radiotherapy (+/- 1 day):\n\n* IV oxaliplatin 85 mg/m² in 2 h on D1\n* IV Leucovorin 200 mg/m² in 2 h on D1, followed by\n* IV 5-FU 400 mg/m² in 10 minutes on D1 followed by\n* IV continuous infusion 5-FU 2400 mg/m² in 46 h","label":"Arm B","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2024-12-01","type":"ACTUAL"},"conditions":["Esophagus Cancer","Unresectable Malignant Neoplasm"],"enrollment":{"count":112,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Durvalumab","otherNames":["IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)"],"type":"DRUG"},{"name":"IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)","otherNames":[],"type":"COMBINATION_PRODUCT"}],"last_update":"2025-11-18","lead_sponsor":"UNICANCER","official_title":"Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer: a Comparative Randomized Phase II Trial","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-05-24","type":"ACTUAL"},"primary_outcomes":[{"measure":"cPFS (centrally reviewed cPFS)","timeFrame":"12-months cPFS"}],"references":[],"start_date":{"date":"2018-12-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer","url":"https://clinicaltrials.gov/study/NCT03777813"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/arion-nct03777813"}